Year None2022202120202019201820172016 Date Latest Press Release December 15, 2022 Eiger BioPharmaceuticals Announces Leadership Change December 8, 2022 Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint December 7, 2022 Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022 November 8, 2022 Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences November 3, 2022 Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update October 24, 2022 Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3 October 11, 2022 Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference October 5, 2022 Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback September 22, 2022 Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference September 6, 2022 Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
